What is next in second- and later-line treatment of metastatic renal cell carcinoma? review of the recent literature.

Mori, Keiichiro; Schmidinger, Manuela; Quhal, Fahad; Egawa, Shin; Shariat, Shahrokh F; Grünwald, Viktor

Mori, Keiichiro; Schmidinger, Manuela; Quhal, Fahad; Egawa, Shin; Shariat, Shahrokh F; Grünwald, Viktor.

Afiliação

Mori K; Department of Urology, Medical University of Vienna, Vienna, Austria.
Schmidinger M; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Quhal F; Department of Urology, Medical University of Vienna, Vienna, Austria.
Egawa S; Department of Urology, Medical University of Vienna, Vienna, Austria.
Shariat SF; Department of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
Grünwald V; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.

Curr Opin Urol ; 31(3): 276-284, 2021 05 01.

Article em En | MEDLINE | ID: mdl-33742984

Assuntos

Carcinoma de Células Renais; Neoplasias Renais; Carcinoma de Células Renais/tratamento farmacológico; Humanos; Neoplasias Renais/tratamento farmacológico; Nivolumabe; Inibidores de Proteínas Quinases/efeitos adversos; Estudos Retrospectivos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Neoplasias Renais Tipo de estudo: Guideline / Observational_studies Limite: Humans Idioma: En Revista: Curr Opin Urol Assunto da revista: UROLOGIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Áustria

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google